← Leaderboards
Adolfo Garcia-Sastre
Jackson Laboratory
$138,961,417
Attributed
$153,393,713
Total exposure
50
Grants
40
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $86.3M · FY2005–25$100M$75M$50M$25M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$304,652,152 · 56
By mechanism
U19$176,564,051 · 29
N01$44,834,574 · 2
P01$25,590,275 · 6
R01$23,283,422 · 7
U01$17,781,060 · 2
U54$13,857,056 · 6
Top collaborators
- Beatriz Marina Avila Fontoura12 shared
- Sumit K Chanda11 shared
- Fred R Hirsch6 shared
- Yuh Min Chook5 shared
- Kristen W Lynch5 shared
- George A Kuchel4 shared
- Duygu Ucar4 shared
- Matthew J Evans3 shared
Others in their field
Top investigators on “Immune Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$680,290,567
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,695,345
- Barton F Haynes · Duke University$456,664,915
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$309,708,725
- Peter B. Gilbert · Fred Hutchinson Cancer Center$192,329,665
Research focus
Immune ResponseVirusResponseVirus DiseasesViralCellsInfectionInfluenzaInfluenzavirusCollaborationsIn VivoProteinsGenesBaseMolecularInfluenza A VirusVirus ReplicationImmuneTechnologyProgramsPathogenSystems BiologyVaccinesMediating
Grant awards (200)
Modulation of Lung Immune Responses to Viral Infection$2,637,774
U19 · FY2025 · AI
SARS-CoV adaptations through a Systems Biology Lens (SYBIL)$2,445,345
U19 · FY2025 · AI · contact PI
A deep longitudinal analysis of next generation influenza vaccines in older adults$1,843,486
U01 · FY2025 · AI
Project 2 - Ex Vivo Analysis of Coronavirus Tropism, Adaptation, Replication, and Host Response$893,131
U19 · FY2025 · AI · contact PI
Zika virus nonstructural protein 5 inhibition of interferon signaling$810,736
R01 · FY2025 · AI
mRNA Nuclear Export Machinery as Target of SARS-CoV-2 Nsp1 Protein$807,958
R01 · FY2025 · AI
Core B - Technology Core$658,945
U19 · FY2025 · AI · contact PI
Project 1 - A systems biology approach to identify early networks and signatures associated with mild and severe SARS-CoV-2 infections in vivo$343,639
U19 · FY2025 · AI · contact PI
Core A - Administrative Core$255,560
U19 · FY2025 · AI · contact PI
Immune phenotyping of responses to influenza virus vaccination and infection$228,824
U19 · FY2025 · AI · contact PI
Core D - Data Management and Bioinformatics Core$148,452
U19 · FY2025 · AI · contact PI
Core C - Modeling Core$145,618
U19 · FY2025 · AI · contact PI
Modulation of Lung Immune Responses to Viral Infection$2,637,774
U19 · FY2024 · AI
SARS-CoV adaptations through a Systems Biology Lens (SYBIL)$2,534,738
U19 · FY2024 · AI · contact PI
A deep longitudinal analysis of next generation influenza vaccines in older adults$2,465,186
U01 · FY2024 · AI
mRNA Nuclear Export Machinery as Target of SARS-CoV-2 Nsp1 Protein$857,199
R01 · FY2024 · AI
Zika virus nonstructural protein 5 inhibition of interferon signaling$812,848
R01 · FY2024 · AI
Core B - Technology Core$785,873
U19 · FY2024 · AI · contact PI
Project 2 - Ex Vivo Analysis of Coronavirus Tropism, Adaptation, Replication, and Host Response$702,405
U19 · FY2024 · AI · contact PI
Vulnerability of SARS- CoV-2 Infection in Lung Cancer Based on Serological Antibody Analyses$599,601
U54 · FY2024 · CA
Project 1 - A systems biology approach to identify early networks and signatures associated with mild and severe SARS-CoV-2 infections in vivo$403,954
U19 · FY2024 · AI · contact PI
Core A - Administrative Core$295,879
U19 · FY2024 · AI · contact PI
Immune phenotyping of responses to influenza virus vaccination and infection$196,104
U19 · FY2024 · AI · contact PI
Core D - Data Management and Bioinformatics Core$186,142
U19 · FY2024 · AI · contact PI
Core C - Modeling Core$160,485
U19 · FY2024 · AI · contact PI
Project 2: Susceptibility of Lung Cancer Cells to SARS- CoV-2 Infection and Antibody-Mediated Neutralization$119,920
U54 · FY2024 · CA · contact PI
Vulnerability of SARS- CoV-2 Infection in Lung Cancer Based on Serological Antibody Analyses$3,271,928
U54 · FY2023 · CA
SARS-CoV adaptations through a Systems Biology Lens (SYBIL)$2,651,463
U19 · FY2023 · AI · contact PI
A deep longitudinal analysis of next generation influenza vaccines in older adults$2,195,905
U01 · FY2023 · AI
Toward a universal influenza virus vaccine based on live attenuated NS1-deleted influenza viruses$1,126,946
R01 · FY2023 · AI · contact PI
Zika virus nonstructural protein 5 inhibition of interferon signaling$854,154
R01 · FY2023 · AI
Core B - Technology Core$817,413
U19 · FY2023 · AI · contact PI
Project 2 - Ex Vivo Analysis of Coronavirus Tropism, Adaptation, Replication, and Host Response$795,700
U19 · FY2023 · AI · contact PI
Project 1 - A systems biology approach to identify early networks and signatures associated with mild and severe SARS-CoV-2 infections in vivo$360,450
U19 · FY2023 · AI · contact PI
Core A - Administrative Core$295,750
U19 · FY2023 · AI · contact PI
Immune phenotyping of responses to influenza virus vaccination and infection$216,944
U19 · FY2023 · AI · contact PI
Core D - Data Management and Bioinformatics Core$192,750
U19 · FY2023 · AI · contact PI
Core C - Modeling Core$189,400
U19 · FY2023 · AI · contact PI
Center for Antiviral Medicines & Pandemic Preparedness (CAMPP)$67,624,156
U19 · FY2022 · AI
Development of CoV inhibitors against non-enzymatic targets$5,121,996
U19 · FY2022 · AI · contact PI
In vivo virology core$3,760,731
U19 · FY2022 · AI · contact PI
Fluomics: The Next Generation$2,648,364
U19 · FY2022 · AI · contact PI
Vulnerability of SARS- CoV-2 Infection in Lung Cancer Based on Serological Antibody Analyses$2,044,217
U54 · FY2022 · CA
A deep longitudinal analysis of next generation influenza vaccines in older adults$1,622,607
U01 · FY2022 · AI
Toward a universal influenza virus vaccine based on live attenuated NS1-deleted influenza viruses$1,126,946
R01 · FY2022 · AI · contact PI
Project 1 - Host-virus networks regulating flu replication and host responses in vivo$484,414
U19 · FY2022 · AI · contact PI
Evaluation of the immune responses to influenza virus vaccines and efficacy of immunotherapeutics in the ferret model$423,750
P01 · FY2022 · AI · contact PI
Project 2: Susceptibility of Lung Cancer Cells to SARS- CoV-2 Infection and Antibody-Mediated Neutralization$395,967
U54 · FY2022 · CA · contact PI
Immune phenotyping of responses to influenza virus vaccination and infection$283,216
U19 · FY2022 · AI · contact PI
Core A - Administrative Core$266,890
U19 · FY2022 · AI · contact PI
ConProject-005$169,374
U19 · FY2022 · AI · contact PI
Admin-Core-001$120,079
U54 · FY2022 · CA
Vulnerability of SARS- CoV-2 Infection in Lung Cancer Based on Serological Antibody Analyses$120,079
U54 · FY2022 · CA
ConProject-004$42,808
U19 · FY2022 · AI · contact PI
Fluomics: The Next Generation$2,648,626
U19 · FY2021 · AI · contact PI
Toward a universal influenza virus vaccine based on live attenuated NS1-deleted influenza viruses$1,153,495
R01 · FY2021 · AI · contact PI
Innate Immune Surveillance of HIV-1 During Transmission and Systemic Infection$563,051
R01 · FY2021 · AI
Project 1 - Host-virus networks regulating flu replication and host responses in vivo$498,282
U19 · FY2021 · AI · contact PI
Fluomics: The Next Generation$449,250
U19 · FY2021 · AI · contact PI
Evaluation of the immune responses to influenza virus vaccines and efficacy of immunotherapeutics in the ferret model$423,750
P01 · FY2021 · AI · contact PI
Innate Immune Surveillance of HIV-1 During Transmission and Systemic Infection$379,532
R01 · FY2021 · AI
Early development of small molecule dendritic cell immunopotentiators for the treatment of solid tumors$370,994
R01 · FY2021 · CA
Core A - Administrative Core$358,127
U19 · FY2021 · AI · contact PI
Early development of small molecule dendritic cell immunopotentiators for the treatment of solid tumors$343,138
R01 · FY2021 · CA
CEIRS: SARS-CoV-2 RESEARCH$308,000
N01 · FY2021 · AI · contact PI
Core G - IOF Management Core$300,000
U19 · FY2021 · AI · contact PI
Project 1 - Host-virus networks regulating flu replication and host responses in vivo$254,250
U19 · FY2021 · AI · contact PI
Vulnerability of SARS- CoV-2 Infection in Lung Cancer Based on Serological Antibody Analyses$3,968,419
U54 · FY2020 · CA
Fluomics: The Next Generation$2,648,396
U19 · FY2020 · AI · contact PI
Core G - IOF Management Core$1,959,638
U19 · FY2020 · AI · contact PI
CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS): UNIVERSAL INFLUENZA RESEARCH EFFORTS$1,319,131
N01 · FY2020 · AI · contact PI
Toward a universal influenza virus vaccine based on live attenuated NS1-deleted influenza viruses$1,262,646
R01 · FY2020 · AI · contact PI
Project 2: Susceptibility of Lung Cancer Cells to SARS- CoV-2 Infection and Antibody-Mediated Neutralization$878,495
U54 · FY2020 · CA · contact PI
Innate Immune Surveillance of HIV-1 During Transmission and Systemic Infection$860,913
R01 · FY2020 · AI
Early development of small molecule dendritic cell immunopotentiators for the treatment of solid tumors$714,132
R01 · FY2020 · CA
Fluomics: The Next Generation$635,916
U19 · FY2020 · AI · contact PI
Splicing and Nuclear Transport of Influenza Virus mRNA$517,918
R01 · FY2020 · AI
Project 1 - Host-virus networks regulating flu replication and host responses in vivo$499,560
U19 · FY2020 · AI · contact PI
Evaluation of the immune responses to influenza virus vaccines and efficacy of immunotherapeutics in the ferret model$423,750
P01 · FY2020 · AI · contact PI
Core A - Administrative Core$358,100
U19 · FY2020 · AI · contact PI
Project 1 - Host-virus networks regulating flu replication and host responses in vivo$271,625
U19 · FY2020 · AI · contact PI
Core G - IOF Management Core$3,029,657
U19 · FY2019 · AI · contact PI
CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS): UNIVERSAL INFLUENZA RESEARCH EFFORTS$2,967,125
N01 · FY2019 · AI · contact PI
Fluomics: The Next Generation$2,648,073
U19 · FY2019 · AI · contact PI
Innate Immune Surveillance of HIV-1 During Transmission and Systemic Infection$861,268
R01 · FY2019 · AI
Early development of small molecule dendritic cell immunopotentiators for the treatment of solid tumors$692,707
R01 · FY2019 · CA
Splicing and Nuclear Transport of Influenza Virus mRNA$517,918
R01 · FY2019 · AI
Project 1 - Host-virus networks regulating flu replication and host responses in vivo$501,276
U19 · FY2019 · AI · contact PI
Chemical intervention of influenza virus RNA nuclear export$500,998
R33 · FY2019 · AI · contact PI
Evaluation of the immune responses to influenza virus vaccines and efficacy of immunotherapeutics in the ferret model$423,750
P01 · FY2019 · AI · contact PI
Core A - Administrative Core$358,125
U19 · FY2019 · AI · contact PI
Project I: Immunity to Influenza in Primary Lung Epithelial Cells$270,819
U19 · FY2019 · AI · contact PI
Core G - IOF Management Core$3,506,294
U19 · FY2018 · AI · contact PI
CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS): UNIVERSAL INFLUENZA RESEARCH EFFORTS$2,865,600
N01 · FY2018 · AI · contact PI
Fluomics: The Next Generation$2,799,687
U19 · FY2018 · AI · contact PI
Innate Immune Surveillance of HIV-1 During Transmission and Systemic Infection$861,892
R01 · FY2018 · AI
Project 1 - Host-virus networks regulating flu replication and host responses in vivo$766,049
U19 · FY2018 · AI · contact PI
Early development of small molecule dendritic cell immunopotentiators for the treatment of solid tumors$737,882
R01 · FY2018 · CA
Core B - Technology Core$587,755
U19 · FY2018 · AI · contact PI
Splicing and Nuclear Transport of Influenza Virus mRNA$517,918
R01 · FY2018 · AI
Chemical intervention of influenza virus RNA nuclear export$499,523
R33 · FY2018 · AI · contact PI
Core C - Modeling Core$447,342
U19 · FY2018 · AI · contact PI
Evaluation of the immune responses to influenza virus vaccines and efficacy of immunotherapeutics in the ferret model$413,325
P01 · FY2018 · AI · contact PI
Project I: Immunity to Influenza in Primary Lung Epithelial Cells$256,755
U19 · FY2018 · AI · contact PI
Interferon signaling inhibition by the Zika virus NS5 protein$211,875
R21 · FY2018 · AI · contact PI
Core A - Administrative Core$211,719
U19 · FY2018 · AI · contact PI
Core D - Data Management and Bioinformatics Core$187,710
U19 · FY2018 · AI · contact PI
CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS)$7,195,513
N01 · FY2017 · AI · contact PI
Multiscale analysis of influenza host-pathogen interactions: Fluomics$5,317,381
U19 · FY2017 · AI · contact PI
Core G - IOF Management Core$1,923,955
U19 · FY2017 · AI · contact PI
Toward a universal influenza virus vaccine based on live attenuated NS1-deleted influenza viruses$1,450,070
R01 · FY2017 · AI · contact PI
Innate Immune Surveillance of HIV-1 During Transmission and Systemic Infection$910,053
R01 · FY2017 · AI
In vivo interrogation of the genetic and biochemical networks controlling influe$747,686
U19 · FY2017 · AI · contact PI
Splicing and Nuclear Transport of Influenza Virus mRNA$517,918
R01 · FY2017 · AI
Chemical intervention of influenza virus RNA nuclear export$500,063
R33 · FY2017 · AI · contact PI
Administrative Core$447,179
U19 · FY2017 · AI · contact PI
Project I: Immunity to Influenza in Primary Lung Epithelial Cells$270,819
U19 · FY2017 · AI · contact PI
Interferon signaling inhibition by the Zika virus NS5 protein$254,250
R21 · FY2017 · AI · contact PI
CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS)$6,633,364
N01 · FY2016 · AI · contact PI
Multiscale analysis of influenza host-pathogen interactions: Fluomics$5,267,031
U19 · FY2016 · AI · contact PI
Core G - IOF Management Core$3,113,807
U19 · FY2016 · AI · contact PI
Splicing and Nuclear Transport of Influenza Virus mRNA$563,157
R01 · FY2016 · AI
In vivo interrogation of the genetic and biochemical networks controlling influe$466,710
U19 · FY2016 · AI · contact PI
Administrative Core$346,912
U19 · FY2016 · AI · contact PI
In Vivo Evaluation of the Protective Efficacy of HA Immunogens and Antibodies$322,706
P01 · FY2016 · AI · contact PI
Project I: Immunity to Influenza in Primary Lung Epithelial Cells$251,661
U19 · FY2016 · AI · contact PI
Chemical intervention of influenza virus RNA nuclear export$198,430
R21 · FY2016 · AI · contact PI
CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS)$7,420,286
N01 · FY2015 · AI · contact PI
Multiscale analysis of influenza host-pathogen interactions: Fluomics$5,299,649
U19 · FY2015 · AI · contact PI
Core G - IOF Management Core$4,569,635
U19 · FY2015 · AI · contact PI
Administrative Core$701,569
U19 · FY2015 · AI · contact PI
In vivo interrogation of the genetic and biochemical networks controlling influe$668,220
U19 · FY2015 · AI · contact PI
In Vivo Evaluation of the Protective Efficacy of HA Immunogens and Antibodies$319,709
P01 · FY2015 · AI · contact PI
Chemical intervention of influenza virus RNA nuclear export$263,500
R21 · FY2015 · AI · contact PI
Project I: Immunity to Influenza in Primary Lung Epithelial Cells$261,171
U19 · FY2015 · AI · contact PI
CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND SURVEILLANCE (CEIRS)$7,336,466
N01 · FY2014 · AI · contact PI
Multiscale analysis of influenza host-pathogen interactions: Fluomics$5,286,096
U19 · FY2014 · AI · contact PI
Administrative Core$749,481
U19 · FY2014 · AI · contact PI
In vivo interrogation of the genetic and biochemical networks controlling influe$513,586
U19 · FY2014 · AI · contact PI
In Vivo Evaluation of the Protective Efficacy of HA Immunogens and Antibodies$417,167
P01 · FY2014 · AI · contact PI
Multiscale analysis of influenza host-pathogen interactions: Fluomics$4,822,003
U19 · FY2013 · AI · contact PI
In vivo interrogation of the genetic and biochemical networks controlling influe$470,264
U19 · FY2013 · AI · contact PI
TRIM mediated host antiviral responses during influenza virus infections$446,554
U19 · FY2013 · AI · contact PI
Inhibition of innate immunity by hemorrhagic fever arboviruses$371,226
U54 · FY2013 · AI · contact PI
In Vivo Evaluation of the Protective Efficacy of HA Immunogens and Antibodies$302,178
P01 · FY2013 · AI · contact PI
Administrative Core$106,820
U19 · FY2013 · AI · contact PI
TRIM mediated host antiviral responses during influenza virus infections$468,231
U19 · FY2012 · AI · contact PI
Inhibition of innate immunity by hemorrhagic fever arboviruses$370,730
U54 · FY2012 · AI · contact PI
In Vivo Evaluation of the Protective Efficacy of HA Immunogens and Antibodies$328,073
P01 · FY2012 · AI · contact PI
Inhibition of innate immunity by hemorrhagic fever arboviruses$446,977
U54 · FY2011 · AI · contact PI
TRIM mediated host antiviral responses during influenza virus infections$436,591
U19 · FY2011 · AI · contact PI
MOLECULAR AND BIOLOGICAL CHARACTERIZATION OF PANDEMIC FLU$3,963,191
P01 · FY2010 · AI · contact PI
Center for Research on Influenza Pathogenesis$2,688,983
N01 · FY2010 · AI · contact PI
Live attenuated vaccines for epidemic and pandemic flu$1,948,534
U01 · FY2010 · AI · contact PI
TRIM mediated host antiviral responses during influenza virus infections$438,624
U19 · FY2010 · AI · contact PI
Virulence factors of influenza virus: The NS1 protein$319,685
R01 · FY2010 · AI · contact PI
Center for Research on Influenza Pathogenesis$6,100,106
N01 · FY2009 · AI · contact PI
MOLECULAR AND BIOLOGICAL CHARACTERIZATION OF PANDEMIC FLU$3,972,316
P01 · FY2009 · AI · contact PI
Live attenuated vaccines for epidemic and pandemic flu$1,914,536
U01 · FY2009 · AI · contact PI
TRIM mediated host antiviral responses during influenza virus infections$437,546
U19 · FY2009 · AI · contact PI
Virulence factors of influenza virus: The NS1 protein$322,914
R01 · FY2009 · AI · contact PI
MOLECULAR AND BIOLOGICAL CHARACTERIZATION OF SPANISH FLU$2,397,637
P01 · FY2008 · AI · contact PI
Live attenuated vaccines for epidemic and pandemic flu$1,862,415
U01 · FY2008 · AI · contact PI
Viral Pathogenesis and Therapeutics$1,149,418
U54 · FY2008 · AI · contact PI
Induction of Immunity by Influenza Virus$567,258
U19 · FY2008 · AI · contact PI
Core--Pilot Projects$361,147
U19 · FY2008 · AI · contact PI
Virulence factors of influenza virus: The NS1 protein$322,914
R01 · FY2008 · AI · contact PI
NS1 and M Genes of the 1918 Influenza Virus: Role in Evasion of Innate Immunity$211,235
P01 · FY2008 · AI · contact PI
MOLECULAR AND BIOLOGICAL CHARACTERIZATION OF SPANISH FLU$2,382,532
P01 · FY2007 · AI · contact PI
Live attenuated vaccines for epidemic and pandemic flu$1,846,896
U01 · FY2007 · AI · contact PI
Induction of Immunity by Influenza Virus$567,511
U19 · FY2007 · AI · contact PI
Core--Pilot Projects$361,310
U19 · FY2007 · AI · contact PI
Virulence factors of influenza virus: The NS1 protein$329,169
R01 · FY2007 · AI · contact PI
NS1 and M Genes of the 1918 Influenza Virus: Role in Evasion of Innate Immunity$209,887
P01 · FY2007 · AI · contact PI
MOLECULAR AND BIOLOGICAL CHARACTERIZATION OF SPANISH FLU$2,392,160
P01 · FY2006 · AI · contact PI
Live attenuated vaccines for epidemic and pandemic flu$2,081,495
U01 · FY2006 · AI · contact PI
Induction of Immunity by Influenza Virus$588,688
U19 · FY2006 · AI · contact PI
Core--Pilot Projects$374,795
U19 · FY2006 · AI · contact PI
Virulence factors of influenza virus: The NS1 protein$339,000
R01 · FY2006 · AI · contact PI
The NS1 and M Genes of the 1918 Influenza Virus$215,816
P01 · FY2006 · AI · contact PI
MOLECULAR AND BIOLOGICAL CHARACTERIZATION OF SPANISH FLU$2,387,040
P01 · FY2005 · AI
Induction of Immunity by Influenza Virus$578,763
U19 · FY2005 · AI
Core--Pilot Projects$368,476
U19 · FY2005 · AI
The NS1 and M Genes of the 1918 Influenza Virus$210,293
P01 · FY2005 · AI
MOLECULAR AND BIOLOGICAL CHARACTERIZATION OF SPANISH FLU$2,757,597
P01 · FY2004 · AI
Induction of Immunity by Influenza Virus$569,104
U19 · FY2004 · AI
Core--Pilot Projects$362,326
U19 · FY2004 · AI
VIRULENCE FACTORS OF INFLUENZA VIRUS--THE NS1 PROTEIN$296,625
R01 · FY2004 · AI
The NS1 and M Genes of the 1918 Influenza Virus$242,938
P01 · FY2004 · AI
VIRULENCE FACTORS OF INFLUENZA VIRUS--THE NS1 PROTEIN$294,401
R01 · FY2003 · AI
VIRULENCE FACTORS OF INFLUENZA VIRUS--THE NS1 PROTEIN$278,955
R01 · FY2002 · AI
ATTENUATION IMMUNOGENICITY$149,825
P01 · FY2002 · AI
TRANSFECTANT INFLUENZA VIRUSES IN CANCER THERAPY$99,349
R29 · FY2002 · CA
Inhibition of Host Antiviral Responses by Human Respiratory Syncytial Virus$0
P01 · FY2002 · AI
VIRULENCE FACTORS OF INFLUENZA VIRUS--THE NS1 PROTEIN$294,193
R01 · FY2001 · AI
ATTENUATION IMMUNOGENICITY$149,825
P01 · FY2001 · AI
TRANSFECTANT INFLUENZA VIRUSES IN CANCER THERAPY$95,451
R29 · FY2001 · CA
VIRULENCE FACTORS OF INFLUENZA VIRUS--THE NS1 PROTEIN$292,177
R01 · FY2000 · AI
ATTENUATION IMMUNOGENICITY$149,825
P01 · FY2000 · AI
TRANSFECTANT INFLUENZA VIRUSES IN CANCER THERAPY$118,275
R29 · FY2000 · CA